The Vetr crowd on Tuesday downgraded their rating for Biogen Inc BIIB from 5 stars (Strong Buy), issued five days ago, to 4 stars (Buy). Crowd sentiment for Biogen is unanimously positive, with 100 percent of Vetr user ratings bullish.
Share price in Biogen fell sharply in the first two days of February. It has slowly climbed about $5 since then, finishing Tuesday at $266.11.
Today also marked an upgrade from analysts with Citigroup, who raised Biogen's rating from Neutral to Buy.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for the stock is up at $295.39, which is still below the average analyst target price of $332.00. Less than 2 percent of Vetr users are holding BIIB in their watch lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
